Pricing Log in Create free account
Friday 6 November 2026 Export JAZZ’s income statement to Excel — free account

Jazz Pharmaceuticals PLC

JAZZ Healthcare Biotechnology

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.

Revenue
+10.4%
EPS
−280.5%
Free cash flow
−60.4%
Total debt
+3.88%

Quarter to September 2026, against a year earlier

236.86 9.54 +4.20%
Market cap
$14.6B
P/E
62.6×
Fwd P/E
35.9×
Dividend yield
—
F-score
5/9
Altman Z
1.37
Beneish M
−3.03
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Revenue by regions Fiscal 2024

  • U.S.
  • Europe
  • All other

Every year since 2009 →

Insider Decisions last twelve months

Sold, $m 50.52
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 2 — 4 2 1 5 3 1 2 3 2 2
Insider Ownership 4.70%

Capital & Financial Ratios $m

Size
Market Cap 14,590.00
Revenue ttm 4,718.19
Net income ttm 205.95
Free cash flow ttm 664.54
Net debt Q 2,713.00
Valuation
P/E 62.55 (above 35: high)
Forward P/E 35.90 (above 35: high)
Price / sales 3.12
Forward P/S Powerpack
Price / FCF 22.16
Price / book 3.51
Financial health
Current ratio Q 1.82 (at or above 1.5: strong)
Debt / equity Q 1.33
Interest coverage Q (9.09)
Growth
Revenue growth Q +10.38% (above 0%: growing)
Operating income growth Q −818.96% (below 0%: shrinking)
EPS, this year +78.74% (at or above 15%: strong)
EPS, next year A +77.74% (at or above 15%: strong)
Revenue, next year A +11.00% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +48.85% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.7×, against a ten-year median of 4.0×; over the ten years it ranged from 2.3× in 2025 to 7.2× in 2017.
P/E against its own 10 years 90.32%
10-year low 10-year high
P/S against its own 10 years 48.40%
10-year low 10-year high
P/B against its own 10 years 79.83%
10-year low 10-year high
EV/Sales against its own 10 years 37.70%
10-year low 10-year high
EV/FCF against its own 10 years 92.37%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1,626 2,993 2,442 2,856
Receivables 706 717 831 874
Inventory 597 480 417 454
Other 321 262 324 258
3,435 4,629 4,166 4,613
2023 2024 2025 Q'26
Payables 103 78 122 380
ST’ Debt 605 31 1,030 1,017
Other — — — —
1,537 1,039 2,243 2,533

Compound Annual Growth %

10y 5y 3y
Sales 12.41% 12.54% 5.26%
Cash Flow 9.81% 8.55% 2.15%
Earnings 0.00% 0.00% 0.00%
Book Value 10.45% 3.37% 11.86%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −4.09 Actual −3.88

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 6.62 6.64 Beat by 0.02
Q1 FY26 4.67 6.34 Beat by 1.67
Q2 FY26 6.04 5.71 Miss by 0.33
Q3 FY26 −4.09 −3.88 Beat by 0.21
Q4 FY26 6.84 — Reports 23 February 2027

EPS $

Mar Jun Sep Dec Year
’26 4.43 2.78 (7.47) — —
’25 (1.52) (11.74) 4.08 3.21 (5.84)
’24 (0.23) 2.49 3.42 3.11 8.65
’23 1.04 1.52 2.14 1.42 6.10
’22 0.03 0.55 (0.31) (3.82) (3.58)
’21 2.09 (6.11) (0.86) (0.57) (5.52)
’20 (2.82) 2.06 2.64 2.33 4.22
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 1,069 1,208 1,243 — —
’25 898 1,046 1,126 1,198 4,268
’24 902 1,024 1,055 1,088 4,069
’23 893 957 972 1,012 3,834
’22 814 933 941 972 3,659
’21 608 752 838 897 3,094
’20 535 562 601 666 2,364
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 408 416 506 — —
’25 430 89 475 362 1,356
’24 267 331 399 399 1,396
’23 321 297 307 167 1,092
’22 209 303 418 342 1,272
’21 285 42 274 178 779
’20 273 183 258 186 900
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 389 321 493 — —
’25 391 (782) 1,245 (538) 316
’24 250 324 388 385 1,348
’23 316 291 303 139 1,049
’22 172 222 423 (42) 774
’21 283 35 248 168 733
’20 53 77 245 146 520
Fiscal quarters ending in the months shown.

Valuation

The price implies free cash flow after share-based pay growing 17.2% a year for ten years. It grew 5.2% a year over the last ten.

Implied
17.2%
10 years, reported
5.2%
Open the model

Target Price Range

Analyst price targets

Recommendation Rating

1.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 1,488 1,619 1,891 2,162 2,364 3,094 3,659 3,834 4,069 4,268 4,718 +12.4% 4,737 5,016 5,458 +8.5%
Gross margin, % 92.92 93.19 93.57 94.08 93.70 85.76 85.23 88.64 89.05 88.21 89.09 (4.7) pt
EBT 532 441 529 454 275 (113) (373) 298 470 (628) 260 n/m
EBT margin, % 35.78 27.25 28.00 21.02 11.64 (3.65) (10.19) 7.77 11.56 (14.71) 5.51 (50.5) pt
Net income 397 488 447 523 239 (330) (224) 415 560 (356) 206 n/m
Per share, $
Per share, $ Revenue 24.59 26.97 31.53 38.09 42.42 51.84 58.51 60.58 65.80 69.98 72.92 +12.3%
Earnings 6.56 8.13 7.45 9.22 4.28 (5.52) (3.58) 6.55 9.06 (5.84) 3.64 n/m
Cash flow 9.79 11.55 13.32 13.68 16.15 13.04 20.34 17.25 22.57 22.23 26.16 +9.5%
Capex (3.03) (1.90) (1.39) (2.96) (6.81) (0.76) (7.97) (0.68) (0.78) (17.05) (15.89) +21.2%
Free cash flow 6.76 9.65 11.93 10.72 9.34 12.28 12.37 16.57 21.80 5.18 10.27 (2.9%)
Book value 31.03 45.20 45.98 54.82 65.69 66.43 49.34 59.04 66.20 70.82 64.79 +9.6%
Shares, m 61 60 60 57 56 60 63 63 62 61 63 +0.1%
Valuation, ×
Valuation, × P/E 17.31 16.90 16.62 16.19 38.29 0.00 0.00 19.38 13.52 0.00 62.55 13.8
P/S 4.53 5.09 3.93 3.92 3.89 2.46 2.67 2.10 1.87 2.43 3.12 3.3
P/B 3.59 3.04 2.70 2.72 2.51 1.92 3.17 2.15 1.86 2.40 3.51 2.6
EV/Sales 5.61 5.70 4.34 4.16 3.87 4.22 4.00 3.16 2.64 3.11 3.70 4.1
EV/FCF 20.41 15.93 11.60 14.80 17.60 17.82 18.90 11.55 7.96 42.02 26.24 17.9
Cash, $m
Cash, $m Operating cash flow 592 693 799 776 900 779 1,272 1,092 1,396 1,356 1,692 +9.6%
Capex (183) (114) (84) (168) (379) (46) (498) (43) (48) (1,040) (1,028) +21.3%
Free cash flow 409 579 715 608 520 733 774 1,049 1,348 316 665 (2.8%)
Balance, $m
Balance, $m Working capital 491 674 889 1,266 2,186 1,802 1,673 1,899 3,590 1,924 2,080 +16.4%
Net debt 1,604 980 772 530 (38) 5,458 4,843 4,087 3,116 2,916 2,713 +6.9%
Shareholders’ equity 1,877 2,713 2,757 3,111 3,660 3,965 3,086 3,737 4,094 4,319 4,192 +9.7%
Returns, %
Returns, % ROA 9.76 9.83 8.66 9.74 3.95 (3.50) (1.94) 3.96 4.88 (3.01) 1.76 (12.8) pt
ROIC 10.62 8.95 10.89 9.14 6.52 1.13 (0.52) 4.62 6.21 (3.72) 3.86 (14.3) pt
ROE 22.83 21.25 16.35 17.84 7.05 (8.65) (6.36) 12.89 14.58 (8.47) 5.05 (31.3) pt
People
People Employees 1,040 1,210 1,360 1,620 1,940 3,200 2,800 2,800 2,800 2,890 — +12.0%
Revenue/emp, $m 1.43 1.34 1.39 1.33 1.22 0.97 1.31 1.37 1.45 1.48 — +0.4%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Business profile

Updated

Jazz Pharmaceuticals is a biopharmaceutical company focused on medicines for rare diseases, including sleep disorders, epilepsy and cancer. Founded in 2003 and headquartered in Ireland, it is led by President and Chief Executive Officer Renee D. Gala.

Its sleep medicines include Xywav, prescribed for certain symptoms of narcolepsy and for adults with idiopathic hypersomnia, a disorder involving excessive daytime sleepiness. Xyrem is another medicine for narcolepsy. Both are shipped directly to patients or caregivers by a certified specialty pharmacy rather than stocked in retail pharmacies.

Where the money comes from and where it goes Fiscal 2024

Fiscal 2024: revenue by regions, and margins
U.S. 3,660 89.95%
Europe 313 7.69%
All other 96 2.36%
Gross margin 89.05%
Operating margin 17.61%
Pre-tax margin 11.56%

Revenue by segment since 2009

Jazz Pharmaceuticals PLC vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
EXEL Exelixis, Inc. $16.8B 19.9× 20.2× +10.19% (above 0%: growing) +22.22% (above 0%: growing) −4.83% (below 0%: shrinking) 96.02% 40.75% Compare
ASND Ascendis Pharma A/S $16.6B 18.3× 15.4× +119.88% (above 0%: growing) n/m +2,335.93% (above 0%: growing) 91.85% 64.98% Compare
JAZZ Jazz Pharmaceuticals PLC $14.6B 62.6× 35.9× +10.38% (above 0%: growing) n/m −60.40% (below 0%: shrinking) 91.10% (33.26%)
BBIO BridgeBio Pharma, Inc. $14.5B — (loss-making) — (loss-making) +192.60% (above 0%: growing) n/m +60.46% (above 0%: growing) 94.21% (3.30%) Compare
HALO Halozyme Therapeutics, Inc. $14.0B 29.5× 17.9× +39.15% (above 0%: growing) +45.64% (above 0%: growing) −58.64% (below 0%: shrinking) 83.27% 59.83% Compare
TECH Bio-Techne Corp $11.4B 62.2× 54.2× +1.33% (above 0%: growing) n/m −6.83% (below 0%: shrinking) 65.82% 23.13% Compare
SMMT Summit Therapeutics PLC $11.3B — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −112.80% (below 0%: shrinking) 0.00% 0.00% Compare
KYMR Kymera Therapeutics, Inc. $10.9B — (loss-making) — (loss-making) +466.40% (above 0%: growing) n/m −186.64% (below 0%: shrinking) 100.00% 0.00% Compare
BMRN BioMarin Pharmaceutical Inc. $10.9B — (loss-making) 32.7× +32.02% (above 0%: growing) n/m −52.25% (below 0%: shrinking) 79.95% (8.01%) Compare
Median of peers $12.7B 24.7× 20.2× +35.59% — −29.54% 87.56% 11.57%

All 621 Biotechnology stocks →

From the latest earnings call

Updated

  • CFO Phil Johnson said limited uptake of high-sodium generics and continued Xywav patient additions contributed to Jazz’s higher revenue guidance.
  • Johnson said higher sales of royalty-bearing oncology products reduced adjusted gross margin, while Jazz increased investment in its commercial portfolio and research.

Pay and ownership Proxy statement filed 8 June 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2024 15.53m 17.26m 74.61
2023 15.34m (2.50m) 74.52
2022 17.33m 26.32m 96.52
2021 15.68m 4.92m 77.19

Ownership

Directors and executive officers, together 4.10%
BlackRock, Inc.50 Hudson YardsNew York, NY 9.30%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Jazz Pharmaceuticals PLC (JAZZ) Latest News

3 Nov

Impact 4 · · Moby
Impact 3 · · Simply Wall St.
Impact 3 · · GuruFocus.com
Impact 3 · · Zacks

2 Nov

Impact 4 · · The Motley Fool transcript
Impact 3 · · Simply Wall St.
Impact 3 · · MarketBeat transcript
Impact 3 · · Simply Wall St.
Impact 3 · · StockStory
Impact 3 · · PR Newswire

27 Oct

Impact 4 · · The Motley Fool
Impact 3 · · Zacks

26 Oct

Impact 3 · · Zacks

23 Oct

Impact 4 · · PR Newswire

21 Oct

Impact 3 · · Zacks

19 Oct

Impact 3 · · PR Newswire

16 Oct

Impact 3 · · Zacks
Impact 3 · · Zacks

15 Oct

Impact 4 · · Simply Wall St.

13 Oct

Impact 4 · · TheStreet

20 Sep

Impact 4 · · MarketBeat
Impact 4 · · MarketBeat

18 Sep

Impact 4 · · The Motley Fool

17 Sep

Impact 4 ·

14 Sep

Impact 3 ·

11 Sep

Impact 3 ·

4 Sep

Impact 4 ·

1 Sep

Impact 3 ·

31 Aug

Impact 4 ·

28 Aug

Impact 4 ·

JAZZ metrics, ten years each

stockrow.com/JAZZ · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com